表紙
市場調査レポート

ポイントオブケア診断検査動向

Point of Care Diagnostic Testing Sector Trends

発行 TriMark Publications 商品コード 220787
出版日 ページ情報 英文 189 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
ポイントオブケア診断検査動向 Point of Care Diagnostic Testing Sector Trends
出版日: 2011年11月01日 ページ情報: 英文 189 Pages
概要

当レポートでは、ポイントオブケア(POC)市場の現状と予測、成長率、主要製品や研究開発の最新情報、市場の機会と課題などについて、概略下記の内容でお届けいたします。

第1章 概要

第2章 ポイントオブケア診断検査概要

  • 主な動向
    • 現在の市場動向と促進因子
    • POCTの有効性
    • POCTの新しい成長分野
    • 臨床施設におけるPOCTの利点
    • 価格、償還問題
    • 顧客セグメント
  • 世界のポイントオブケア市場
  • 地域的分布
  • 新興技術
  • POCTの課題
  • POCTの問題点
    • POCTの場所
    • 技術開発のマイルストーン
    • ラボから患者への分散化促進因子
    • 償還拡充
    • POCTの競合環境
  • POCTの将来

第3章 POCTと即時検査市場:市場分析サマリー:規模、背景、成長、シェア、競合企業

  • 世界のポイントオブケア市場

第4章 米国のポイントオブケア市場

第5章 欧州のポイントオブケア市場

第6章 日本のポイントオブケア市場

第7章 中国のポイントオブケア市場

第8章 インドのポイントオブケア市場

第9章 その他の諸国のポイントオブケア市場

第10章 救命救急におけるポイントオブケアの役割

  • ポイントオブケアの技術多様性
    • 幅広いPOCTアッセイ
    • 単一プラットフォームにおける試験の課題
    • 試験プラットフォームとの接続性
    • POCT使用による臨床転帰の改善
    • 将来の発展
  • 救命救急に対応するポイントオブケア
    • 救命救急検査のニーズ
    • 主な設備
    • 主な利点
    • 標準化システム
  • ポイントオブケア対セントラルラボ検査
    • POCTの財政的利点
    • POCTへの移行は正当化されるか
    • 全体的コスト面でのメリット
    • 臨床医によるより多くの時間確保
    • 将来の政策

第11章 ポイントオブケア動向と予測

第12章 ポイントオブケア部門のビジネス動向

  • 部門統合
  • 買収・ライセンス契約・パートナーシップ
  • 理想的買収プロファイル
  • POCTにおける製品幅
  • POCT事業から撤退した企業
  • 市場浸透度の上昇
  • 欧州での営業コスト
  • 欧州における診断検査の発展因子
  • 欧州における償還
  • 欧州におけるコスト抑制
  • 競合優位性をもたらす重要なファクター
  • POCTにおける営業戦略

第13章 バイオテクノロジー業界動向

  • 医薬品業界動向

第14章 政府の規制

第15章 第3者による償還の制限が売上を阻害

  • POCT試薬および装置の販売に影響を及ぼす第3者償還
  • 償還コスト分類
  • ポイントオブケア製品ラインの償還図式

第16章 ビジネス障壁

  • 顧客の集中
  • 他社との激しい競争
  • 知的財産権の保護
  • 医師の受け入れ
  • 現在のPOCT市場の成長水準が将来の成長を約束するものではない
  • 技術プラットフォームにおける追加アプリケーション
  • 成長管理
  • マーケティングインフラ開発の難しさ

第17章 企業プロファイル

第18章 FDAが現在免除している検査

図表

目次
Product Code: TMRPOCST11-1101

Abstract

Point of care testing enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. The purpose of this TriMark Publications report is to describe the sector trends within the point of care testing (POCT) diagnostic market. It examines those measurement devices and their reagents and supplies that are utilized in hospitals, clinics, commercial laboratories and research institutions to detect cells and proteins for the purpose of diagnosis and monitoring of disease. This study includes all of the generally-accepted clinical analytical activities that are currently in use today. Additionally, an analysis of business and technology trends and developing areas of point of care and HPV testing is provided, along with a review of the market for point of care testing equipment and supplies in the clinical and research market segments, using screening reagents and instruments for analysis of individual components in blood, serum or plasma. This report defines U.S. and global market dollar sales volume and analyzes factors that influence the size and growth of market segments.

METHODOLOGY

The author of this report holds a Ph.D. in biochemistry from the University of Minnesota and has had post-doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine, and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He also has many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior level management positions in biotech and medical service companies. The editor of this report is a Ph.D. in biochemistry from the University of Liverpool with many decades of experience in science writing and as a medical industry analyst.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. Scope of This Report
  • 1.3. Objectives
  • 1.4. Methodology
  • 1.5. Executive Summary

2. Overview of Point of Care Diagnostic Testing

  • 2.1. Key Issues in the Point of Care Diagnostic Testing Sector
    • 2.1.1. Current Market Trends and Drivers
    • 2.1.2. Effectiveness of POCT
    • 2.1.3. New Growth Areas for POCT
    • 2.1.4. Advantages of POCT in a Clinical Setting
    • 2.1.5. Pricing and Reimbursement Issues
    • 2.1.6. Key Customer Segments
  • 2.2. Global Point of Care Marketplace
  • 2.3. Shifts from Central Lab Testing to POCT
  • 2.4. Geographical Distribution
  • 2.5. Emerging New Technologies
  • 2.6. Challenges of POCT
  • 2.7. Key Issues for POCT
    • 2.7.1. Locations of POCT
    • 2.7.2. Milestones in Technology Development
    • 2.7.3. Drive for Decentralization from Lab to Patient
    • 2.7.4. Expanded Reimbursement
    • 2.7.5. Competitive Landscape for POCT
  • 2.8. The Future of POCT

3. POC and Rapid Testing Market: Summary of Market Analysis: Size, Background, Growth, Share and Competitors

  • 3.1. Global POCT Market

4. U.S. POCT Market

5. European POCT Market

6. Japanese POCT Market Sector Trends

7. Chinese POCT Market Sector Trends

8. Indian POCT Market Sector Trends

9. The Rest of the World (ROW) POCT Market

10. The Role of POCT in Critical Care

  • 10.1. Technological Diversity in POCT
    • 10.1.1. The Wide Range of Point of Care Assays
    • 10.1.2. Challenge of Testing on a Single Platform
    • 10.1.3. Connectivity with Testing Platforms
    • 10.1.4. Improvement in Clinical Outcomes with Use of POCT
    • 10.1.5. Future Developments
  • 10.2. Point of Care Addresses Critical Requirements
    • 10.2.1. Needs in Critical Care Testing
    • 10.2.2. Point of Care Instrument Key Elements
    • 10.2.3. Key Advancements--Menu, Quality Assurance (QA), Connectivity, Internet Access
    • 10.2.4. Standardized System for All Testing Locations
  • 10.3. POCT versus Central Laboratory Testing
    • 10.3.1. The Financial Advantages of POCT
    • 10.3.2. Is the Shift Towards Point of Care Justified?
    • 10.3.3. Overall Cost Benefit
    • 10.3.4. More Available Time for Clinical Practitioners
    • 10.3.5. Future Policies

11. POCT Sector Trends and Market Predictions

12. Business Trends in the Point of Care Sector

  • 12.1. Sector Consolidation
  • 12.2. Acquisition, License Agreements, Internal Development and Partnerships
  • 12.3. The Ideal Acquisition Profile
    • 12.3.1. Markets of Interest for Acquisition of POCT
    • 12.3.2. Key M&A Steps
  • 12.4. Product Breadth in POCT
  • 12.5. Companies Exiting From POCT
  • 12.6. Increased Market Penetration
  • 12.7. Costs of Doing Business in Europe
  • 12.8. Drivers of European Diagnostics Testing
  • 12.9. European Reimbursement Practices
  • 12.10. Cost Containment in Europe
  • 12.11. Significant Factors that Provide Competitive Advantage
  • 12.12. Sales and Marketing Strategies for POCT
    • 12.12.1. North American Market
    • 12.12.2. International Markets
      • 12.12.2.1. Europe
      • 12.12.2.2. Central and South America
      • 12.12.2.3. Asia-Pacific

13. Biotechnology Industry Trends

  • 13.1. Pharmaceutical Industry Trends

14. Government Regulation

  • 14.1. Government Regulation
    • 14.1.1. U.S. Regulation
      • 14.1.1.1. Importing Medical Devices into the U.S.
      • 14.1.1.2. Exporting Medical Devices from the U.S.
    • 14.1.2. E.U. Regulations
    • 14.1.3. Japanese Regulations
    • 14.1.4. Korean Regulations
  • 14.2. Post Filing Regulations for Point of Care Devices
  • 14.3. Exporting Unapproved POCTs
  • 14.4. Analyte Specific Reagents (Home Brew Tests)
  • 14.5. Medical Device Registration
  • 14.6. Product Labeling
  • 14.7. Punitive FDA Actions
  • 14.8. Clinical Laboratory Improvement Act of 1988 and State Laboratory Laws
  • 14.9. Impact of Regulations on the Industry
  • 14.10. Minimizing Regulatory Barriers
  • 14.11. Waived Testing

15. Limited Reimbursements by Third-Party Payers Obstruct Sales

  • 15.1. Third-Party Reimbursement Impact on POCT Reagents and Devices Sales
  • 15.2. Reimbursement Codes Classification
  • 15.3. Point of Care Product Line Reimbursement Picture

16. Barriers to Business

  • 16.1. Concentration of Customers
  • 16.2. Intense Competition from Other Companies
  • 16.3. Protection of Intellectual Property Rights
  • 16.4. Physician Acceptance
  • 16.5. Current Levels of Market Growth for POCT Procedures May Not be Indicative of Future Growth
  • 16.6. Additional Applications of Technology Platform
  • 16.7. Management of Growth
  • 16.8. Difficulty of Establishing a Marketing Infrastructure

17. Company Profiles

  • 17.1. Abaxis, Inc.
  • 17.2. Abbott Diagnostics
  • 17.3. Accumetrics, Inc.
  • 17.4. Accurex Biomedical Pvt. Ltd.
  • 17.5. AgaMatrix
  • 17.6. Akers Bioscience, Inc. (ABI)
  • 17.7. Alfa Scientific Design, Inc.
  • 17.8. Alere Health, LLC
  • 17.9. Ambri Ltd.
  • 17.10. American Bio Medica Corporation
  • 17.11. Ani Biotech
  • 17.12. Apogent Technologies
  • 17.13. Ark Therapeutics
  • 17.14. ARKRAY, Inc.
  • 17.15. Atlas Genetics
  • 17.16. Atonomics A/S
  • 17.17. Avox Systems
  • 17.18. Axis-Shield
  • 17.19. Bayer Corp.
  • 17.20. Beacon Diagnostics, Inc.
  • 17.21. Beckman Coulter
  • 17.22. Binax Corporation
  • 17.23. Biomerica, Inc.
  • 17.24. bioMerieux
  • 17.25. BioScan Screening Systems, Inc.
  • 17.26. Biosite Diagnostics
  • 17.27. British Biocell Holdings
  • 17.28. Caliper Life Sciences
  • 17.29. Calypte Biomedical Corporation
  • 17.30. Chembio Diagnostics, Inc.
  • 17.31. Cholestech
  • 17.32. CompuCyte Corporation
  • 17.33. Cozart Bioscience
  • 17.34. Cygnus Therapeutic Systems
  • 17.35. Cytogen Corporation
  • 17.36. Dade Behring
  • 17.37. Daiichi Sankyo Group
  • 17.38. Denka Seiken Co., Ltd.
  • 17.39. Diagnostic Chemicals Ltd.
  • 17.40. EY Laboratories, Inc.
  • 17.41. Enterix, Inc.
  • 17.42. Focus Diagnostic, Inc.
  • 17.43. GDS Technology
  • 17.44. GenBio
  • 17.45. Genzyme Diagnostics
  • 17.46. Grant Life Sciences, Inc.
  • 17.47. Gryphus Diagnostics, LLC
  • 17.48. Guided Therapeutics, Inc.
  • 17.49. Harring Group Ltd. (HGR)
  • 17.50. Helena Laboratories
  • 17.51. Hema Diagnostic Systems, LLC
  • 17.52. HemoCue, Inc.
  • 17.53. Home Access Health Corp.
  • 17.54. i-STAT Corporation
  • 17.55. ImmunoScience, Inc.
  • 17.56. Instrumentation Laboratory
  • 17.57. International Medical Innovations
  • 17.58. Johnson & Johnson
  • 17.59. LifeAssays AB
  • 17.60. MediSense
  • 17.61. Medisys
  • 17.62. Medix Biochemica
  • 17.63. MedMira Laboratories
  • 17.64. Medtronic
  • 17.65. A Menarini Diagnostics
  • 17.66. Meretek Diagnostics Group
  • 17.67. Meridian Bioscience
  • 17.68. MiniMed
  • 17.69. Mitsubishi Chemical USA, Inc.
  • 17.70. Mitsubishi Kagaku Iatron
  • 17.71. Nanogen (ELITech Group)
  • 17.72. New Horizons Diagnostics
  • 17.73. Nova Biomedical
  • 17.74. OraSure Technologies, Inc.
  • 17.75. Orgenics
  • 17.76. Orion Diagnostica
  • 17.77. PanBio Ltd.
  • 17.78. Phamatech, Inc.
  • 17.79. PharmaNetics, Inc.
  • 17.80. Polymedco, Inc.
  • 17.81. Polymer Technology Systems, Inc.
  • 17.82. Princeton BioMeditech Corporation
  • 17.83. Quest Diagnostics, Inc.
  • 17.84. Quidel Corporation
  • 17.85. Radiometer
  • 17.86. Response Biomedical Corp.
  • 17.87. Roche Diagnostics
  • 17.88. Savyon Diagnostics
  • 17.89. Selfcare, Inc.
  • 17.90. Shionogi & Co., Ltd.
  • 17.91. Siemens Corporation
  • 17.92. Guided Therapeutics (SpectRx, Inc.)
  • 17.93. Spectral Diagnostics
  • 17.94. StatSure Diagnostic Systems, Inc.
  • 17.95. Strategic Diagnostics
  • 17.96. Trinity Biotech, Plc
  • 17.97. Vasamed, Inc.

18. FDA Currently Waived Tests

INDEX OF FIGURES

  • Figure 14.1: Conformity Assessment Route, Annexes and Quality System Standards by IVD Device Category

INDEX OF TABLES

  • Table 2.1: POCT Frequency in Hospitals
  • Table 2.2: Worldwide Distribution of IVD Testing, 2010
  • Table 2.3: Top Thirteen Country IVD Testing Markets, 2010
  • Table 2.4: Common Genotype Techniques
  • Table 2.5: Competitive Landscape for Point of Care Diagnostic Testing
  • Table 3.1: Total Global POCT Market, 2007-2017
  • Table 3.2: Global Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017
  • Table 3.3: Global Revenue Forecasts for POC Blood Gas and Electrolyte Analyzers, 2007-2017
  • Table 3.4: Global Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017
  • Table 3.5: Global Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017
  • Table 3.6: Global Revenue Forecasts for POC Substance/Drug Abuse Testing Device Market, 2007-2017
  • Table 3.7: Global Revenue Forecasts for POC Infectious Disease Testing Devices Market, 2007-2017
  • Table 3.8: Global Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017
  • Table 3.9: Global Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017
  • Table 3.10: Global Revenue Forecasts for POC Fecal Occult Testing Devices Market, 2007-2017
  • Table 3.11: Global Revenue Forecasts for POC Cholesterol Testing Products Market, 2007-2017
  • Table 3.12: Global Market Share Analysis, 2010
  • Table 4.1: Total U.S. POCT Market for Blood Glucose Monitoring Systems, 2007-2017
  • Table 4.2: U.S Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017
  • Table 4.3: U.S Revenue Forecasts for POC Blood Gas and Electrolyte Analyzers, 2007-2017
  • Table 4.4: U.S. Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017
  • Table 4.5: U.S. Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017
  • Table 4.6: U.S. Revenue Forecasts for POC Substance/Drug Abuse Testing Device Market, 2007-2017
  • Table 4.7: U.S. Revenue Forecasts for POC Infectious Disease Testing Devices Market, 2007-2017
  • Table 4.8: U.S. Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017
  • Table 4.9: U.S. Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017
  • Table 4.10: U.S. Revenue Forecasts for POC Fecal Occult Testing Devices Market, 2007-2017
  • Table 4.11: U.S. Revenue Forecasts for POC Cholesterol Testing Products Market, 2007-2017
  • Table 4.12: U.S. Market Share Analysis, 2010
  • Table 5.1: Models of Public-Private Partnership in Hospital Provision
  • Table 5.2: European Revenue Forecasts for POCT Market, 2007-2017
  • Table 5.3: European Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017
  • Table 5.4: European Revenue Forecasts for POC Blood Gas and Electrolyte Analyzers, 2007-2017
  • Table 5.5: European Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017
  • Table 5.6: European Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017
  • Table 5.7: European Revenue Forecasts for POC Substance/Drug Abuse Testing Device Market, 2007-2017
  • Table 5.8: European Revenue Forecasts for POC Infectious Disease Testing Devices Market, 2007-2017
  • Table 5.9: European Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017
  • Table 5.10: European Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017
  • Table 5.11: European Revenue Forecasts for POC Fecal Occult Testing Devices Market, 2007-2017
  • Table 5.12: European Revenue Forecasts for POC Cholesterol Testing Products Market, 2007-2017
  • Table 5.13: European Market Share Analysis, 2010
  • Table 6.1: Total Japanese POCT Market, 2007-2017
  • Table 6.2: Japanese Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017
  • Table 6.3: Japanese Revenue Forecasts for POC Blood Gas and Electrolytes Systems Analysis, 2007-2017
  • Table 6.4: Japanese Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017
  • Table 6.5: Japanese Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017
  • Table 6.6: Japanese Revenue Forecasts for POC Substance/Drug Abuse Testing Device Market, 2007-2017
  • Table 6.7: Japanese Revenue Forecasts for POC Infectious Disease Testing Devices Market, 2007-2017
  • Table 6.8: Japanese Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017
  • Table 6.9: Japanese Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017
  • Table 6.10: Japanese Revenue Forecasts for POC Fecal Occult Testing Devices Market, 2007-2017
  • Table 6.11: Japanese Revenue Forecasts for POC Cholesterol Testing Products Market, 2007-2017
  • Table 6.12: Japanese Market Share Analysis, 2010
  • Table 9.1: ROW Revenue Forecasts for POC Market, 2007-2017
  • Table 9.2: ROW Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017
  • Table 9.3: ROW Revenue Forecasts for POC Blood Gas and Electrolytes Systems Analysis, 2007-2017
  • Table 9.4: ROW Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017
  • Table 9.5: ROW Revenue Forecasts for POC Cardiac Marker Devices Market, 2007-2017
  • Table 9.6: ROW Revenue Forecasts for POC Substance/Drug Abuse Testing Devices Market, 2007-2017
  • Table 9.7: ROW Revenue Forecasts for POC Infectious Disease Testing Devices Market, 2007-2017
  • Table 9.8: ROW Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017
  • Table 9.9: ROW Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017
  • Table 9.10: ROW Revenue Forecasts for POC Fecal Occult Testing Devices Market, 2007-2017
  • Table 9.11: ROW Revenue Forecasts for POC Cholesterol Testing Products Market, 2007-2017
  • Table 9.12: ROW Market Share Analysis, 2010
  • Table 10.1: Customized Reports Must Support CAP and JCAHO Requirements
  • Table 17.1: Abaxis, Inc. Financial Figures--Net Sales by Business Sector, 2008-2010
  • Table 17.2: Abaxis, Inc. Financial Figures--Net Sales by Geographic Region, 2008-2010
  • Table 17.3: Abbott Laboratories Financial Figures--Net Sales by Business Sector, 2008-2010
  • Table 17.4: Abbott Laboratories Financial Figures--Net Sales by Geographic Region, 2008-2010
  • Table 17.5: Bayer AG Financial Figures--Net Sales by Business Sector, 2008-2010
  • Table 17.6: Bayer AG Financial Figures--Net Sales by Geographic Region, 2008-2010
  • Table 17.7: Johnson & Johnson Financial Figures--Net Sales by Major Medical and Diagnostics Businesses, 2008-2010
  • Table 17.8: Medtronic Financial Figures--Net Sales by Segment, 2008-2010
  • Table 17.9: Quidel Product Sales Distribution and Sales, 2009 and 2010
  • Table 17.10: Danaher Corporation Financial Figures--Net Sales by Business Sector, 2008-2010
  • Table 17.11: Danaher Corporation Financial Figures--Net Sales by Geographic Region, 2008-2010
  • Table 17.12: Roche Group Financial Figures--Net Sales by Business Sector, 2008-2010
  • Table 17.13: Roche Group Financial Figures--Net Sales by Geographic Region, 2009 and 2010
  • Table 17.14: Roche Group Financial Figures--Net Sales by Sub-Division, 2008-2010
  • Table 2.1: POCT Frequency in Hospitals
  • Table 2.2: Worldwide Distribution of IVD Testing in 2008
  • Table 2.3: Top Twelve Country IVD Testing Markets, 2007
  • Table 2.4: Competitive Landscape for Point of Care Diagnostic Testing
  • Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2008
  • Table 3.2: Number of POCTs in U.S., 2004-2012
  • Table 3.3: Overall In Vitro Diagnostic Testing Market Worldwide, 2007
  • Table 3.4: Largest Diagnostic Companies Worldwide, 2007
  • Table 3.5: Global Point of Care Revenues, 2005-2012
  • Table 3.6: Worldwide Distribution of POCT, 2008
  • Table 3.7: Professional Glucose Testing Market for POCT Worldwide, 2001-2012
  • Table 3.8: U.S. POCT Market, 2000-2012
  • Table 3.9: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location of Analysis, 2008
  • Table 3.10: U.S. POCT by Performance Location, 2008
  • Table 3.11: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2007
  • Table 3.12: U.S. POCT Glucose Testing Market, 2003-2012
  • Table 3.13: U.S. POCT Blood Gas and Electrolytes Market Size, 2003-2012
  • Table 3.14: U.S. POCT Coagulation Market Size, 2003-2012
  • Table 3.15: U.S. POCT Cardiac Markers Market Size, 2003-2012
  • Table 3.16: U.S. POCT Dedicated Primary Care Markers Market Size, 2003-2012
  • Table 3.17: U.S. POCT Urinalysis Market Size, 2003-2012
  • Table 3.18: Manufacturer Market Share U.S. POCT Market, 2008
  • Table 3.19: Manufacturer Market Share U.S. POCT Market Glucose Testing, 2008
  • Table 3.20: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes Market, 2008
  • Table 3.21: Manufacturer Market Share U.S. POCT Coagulation Market, 2008
  • Table 3.22: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2008
  • Table 3.23: Regional Comparison of Healthcare Spending for IVD for Eastern Europe
  • Table 3.24: European POCT Market, 2005-2012
  • Table 3.25: European POCT Diagnostics Market, 2007
  • Table 3.26: Top Twelve Country IVD and POC Testing Markets, 2007
  • Table 3.27: Japan POCT Market, 2005-2012
  • Table 4.1: Customized Reports Must Support CAP and JCAHO Requirements
  • Table 12.1: Products Marketed by Abbott in the Diagnostic Market
  • Table 12.2: Quidel Product Sales Distribution and Sales, 2006-2008
  • Table 12.3: Key Products
Back to Top